FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury
Traumatic brain injury (TBI) is a complex disease that leads to significant mortality and disability worldwide each year. TBI disrupts the normal activity of kinases and molecular signaling pathways, but the effective therapeutic methods for patients remain limited. Nowadays, kinase inhibitors appro...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration
2024-12-01
|
| Series: | Exploration of Drug Science |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100877/100877.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199606057664512 |
|---|---|
| author | Dezhu Gao Yu Shi Zhiliang Wang Weiming Liu |
| author_facet | Dezhu Gao Yu Shi Zhiliang Wang Weiming Liu |
| author_sort | Dezhu Gao |
| collection | DOAJ |
| description | Traumatic brain injury (TBI) is a complex disease that leads to significant mortality and disability worldwide each year. TBI disrupts the normal activity of kinases and molecular signaling pathways, but the effective therapeutic methods for patients remain limited. Nowadays, kinase inhibitors approved by the Food and Drug Administration (FDA) mainly for cancer treatment have shown potential effects in TBI. Preclinical studies suggest their potential in promoting recovery. There are fewer randomized clinical studies that evaluate efficacy. We search the kinase inhibitors approved by the FDA and traumatic brain injury as keywords on websites and analyze associated research. This review explores the therapeutic efficacy of kinase inhibitors, identifies limitations that must be addressed in future research to advance the application of FDA-approved kinase inhibitors, and emphasizes their promising potential. |
| format | Article |
| id | doaj-art-bff1384009d24d728ea13854c6f7a7bf |
| institution | Kabale University |
| issn | 2836-7677 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Open Exploration |
| record_format | Article |
| series | Exploration of Drug Science |
| spelling | doaj-art-bff1384009d24d728ea13854c6f7a7bf2025-02-08T03:28:18ZengOpen ExplorationExploration of Drug Science2836-76772024-12-012685186610.37349/eds.2024.00077FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injuryDezhu Gao0https://orcid.org/0009-0007-9350-8207Yu Shi1https://orcid.org/0009-0006-7073-0465Zhiliang Wang2https://orcid.org/0000-0002-5229-3736Weiming Liu3https://orcid.org/0000-0002-6245-6287Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; Chinese Glioma Genome Atlas Network (CGGA) and Asian Glioma Genome Atlas Network (AGGA), Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; China National Clinical Research Center for Neurological Diseases, Beijing 100070, ChinaTraumatic brain injury (TBI) is a complex disease that leads to significant mortality and disability worldwide each year. TBI disrupts the normal activity of kinases and molecular signaling pathways, but the effective therapeutic methods for patients remain limited. Nowadays, kinase inhibitors approved by the Food and Drug Administration (FDA) mainly for cancer treatment have shown potential effects in TBI. Preclinical studies suggest their potential in promoting recovery. There are fewer randomized clinical studies that evaluate efficacy. We search the kinase inhibitors approved by the FDA and traumatic brain injury as keywords on websites and analyze associated research. This review explores the therapeutic efficacy of kinase inhibitors, identifies limitations that must be addressed in future research to advance the application of FDA-approved kinase inhibitors, and emphasizes their promising potential.https://www.explorationpub.com/uploads/Article/A100877/100877.pdftraumatic brain injurykinase inhibitorneuroinflammationpost-traumatic epilepsyneurobiological deficits |
| spellingShingle | Dezhu Gao Yu Shi Zhiliang Wang Weiming Liu FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury Exploration of Drug Science traumatic brain injury kinase inhibitor neuroinflammation post-traumatic epilepsy neurobiological deficits |
| title | FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury |
| title_full | FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury |
| title_fullStr | FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury |
| title_full_unstemmed | FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury |
| title_short | FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury |
| title_sort | fda approved kinase inhibitors a promising therapeutic avenue for traumatic brain injury |
| topic | traumatic brain injury kinase inhibitor neuroinflammation post-traumatic epilepsy neurobiological deficits |
| url | https://www.explorationpub.com/uploads/Article/A100877/100877.pdf |
| work_keys_str_mv | AT dezhugao fdaapprovedkinaseinhibitorsapromisingtherapeuticavenuefortraumaticbraininjury AT yushi fdaapprovedkinaseinhibitorsapromisingtherapeuticavenuefortraumaticbraininjury AT zhiliangwang fdaapprovedkinaseinhibitorsapromisingtherapeuticavenuefortraumaticbraininjury AT weimingliu fdaapprovedkinaseinhibitorsapromisingtherapeuticavenuefortraumaticbraininjury |